How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approach

Immune checkpoint inhibitors (ICIs) have revolutionized treatment strategies in the field of oncology. Their favourable outcomes in terms of efficacy and side-effect profile can be thwarted by the development of immune-related adverse events (irAEs). Cutaneous irAEs are relatively common in patients...

Full description

Saved in:
Bibliographic Details
Published in:British journal of dermatology (1951) 2023-10, Vol.189 (Suppl 1), p.i3-i10
Main Authors: Kawsar, Anusuya, Hussain, Khawar, Muinonen-Martin, Andrew James, Fearfield, Louise
Format: Article
Language:English
Subjects:
Exanthema - etiology
Humans
Immune Checkpoint Inhibitors - adverse effects
Immunotherapy - adverse effects
Neoplasms - drug therapy
Skin
Skin Diseases - chemically induced
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune checkpoint inhibitors (ICIs) have revolutionized treatment strategies in the field of oncology. Their favourable outcomes in terms of efficacy and side-effect profile can be thwarted by the development of immune-related adverse events (irAEs). Cutaneous irAEs are relatively common in patients undergoing immunotherapy and include common inflammatory dermatoses (e.g. eczematous, psoriasiform and lichenoid phenotypes), maculopapular eruptions, pruritus and immunobullous disorders. Most of these reactions can be managed without ICIs having to be stopped completely; however, there are some life-threatening toxicities that dermatologists and oncologists should be aware of. In this review, we focus on how to recognize the commonly associated cutaneous irAEs, touching upon rarer reactions and red flags; finally, we provide guidance on their management.
ISSN:0007-0963
1365-2133
1365-2133
DOI:10.1093/bjd/ljad257